|
1
|
Veselka J, Anavekar NS and Charron P:
Hypertrophic obstructive cardiomyopathy. Lancet. 389:1253–1267.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Criley JM and Siegel RJ: Has ‘obstruction’
hindered our understanding of hypertrophic cardiomyopathy?
Circulation. 72:1148–1154. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maron BJ: Hypertrophic cardiomyopathy: A
systematic review. JAMA. 287:1308–1320. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wigle ED, Sasson Z, Henderson MA, Ruddy
TD, Fulop J, Rakowski H and Williams WG: Hypertrophic
cardiomyopathy. The importance of the site and the extent of
hypertrophy. A review. Prog Cardiovasc Dis. 28:1–83. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maron MS, Finley JJ, Bos JM, Hauser TH,
Manning WJ, Haas TS, Lesser JR, Udelson JE, Ackerman MJ and Maron
BJ: Prevalence, clinical significance, and natural history of left
ventricular apical aneurysms in hypertrophic cardiomyopathy.
Circulation. 118:1541–1549. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rowin EJ, Maron BJ, Haas TS, Garberich RF,
Wang W, Link MS and Maron MS: Hypertrophic cardiomyopathy with left
ventricular apical aneurysm: Implications for risk stratification
and management. J Am Coll Cardiol. 69:761–773. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yancy CW, Jessup M, Bozkurt B, Butler J,
Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi
JL, et al: 2013 ACCF/AHA guideline for the management of heart
failure: A report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice
Guidelines. J Am Coll Cardiol. 62:e147–e239. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gersh BJ, Maron BJ, Bonow RO, Dearani JA,
Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, et
al: 2011 ACCF/AHA guideline for the diagnosis and treatment of
hypertrophic cardiomyopathy: A report of the American College of
Cardiology Foundation/American Heart Association Task Force on
Practice Guidelines. Circulation. 124:e783–e831. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Minami Y, Kajimoto K, Terajima Y, Yashiro
B, Okayama D, Haruki S, Nakajima T, Kawashiro N, Kawana M and
Hagiwara N: Clinical implications of midventricular obstruction in
patients with hypertrophic cardiomyopathy. J Am Coll Cardiol.
57:2346–2355. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Efthimiadis GK, Pagourelias ED,
Parcharidou D, Gossios T, Kamperidis V, Theofilogiannakos EK, Pappa
Z, Meditskou S, Hadjimiltiades S, Pliakos C, et al: Clinical
characteristics and natural history of hypertrophic cardiomyopathy
with midventricular obstruction. Circ J. 77:2366–2374. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Authors/Task Force members, ; Elliott PM,
Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege
AA, Lafont A, Limongelli G, et al: 2014 ESC Guidelines on diagnosis
and management of hypertrophic cardiomyopathy: The task force for
the diagnosis and management of hypertrophic cardiomyopathy of the
European Society of Cardiology (ESC). Eur Heart J. 35:2733–2779.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liang JJ, Santangeli P and Callans DJ:
Long-term outcomes of ventricular tachycardia ablation in different
types of structural heart disease. Arrhythm Electrophysiol Rev.
4:177–183. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mantica M, Della Bella P and Arena V:
Hypertrophic cardiomyopathy with apical aneurysm: A case of
catheter and surgical therapy of sustained monomorphic ventricular
tachycardia. Heart. 77:481–483. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tokuda M, Kojodjojo P, Tung S, Tedrow UB,
Nof E, Inada K, Koplan BA, Michaud GF, John RM, Epstein LM and
Stevenson WG: Acute failure of catheter ablation for ventricular
tachycardia due to structural heart disease: Causes and
significance. J Am Heart Assoc. 2:e0000722013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maron BJ, Maron MS, Wigle ED and Braunwald
E: The 50-year history, controversy, and clinical implications of
left ventricular outflow tract obstruction in hypertrophic
cardiomyopathy from idiopathic hypertrophic subaortic stenosis to
hypertrophic cardiomyopathy: From idiopathic hypertrophic subaortic
stenosis to hypertrophic cardiomyopathy. J Am Coll Cardiol.
54:191–200. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tengiz I, Ercan E, Alioglu E and Turk UO:
Percutaneous septal ablation for left mid-ventricular obstructive
hypertrophic cardiomyopathy: A case report. BMC Cardiovasc Disord.
6:152006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Spirito P, Rossi J and Maron BJ: Alcohol
septal ablation: In which patients and why? Ann Cardiothorac Surg.
6:369–375. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Seggewiss H and Faber L: Percutaneous
septal ablation for hypertrophic cardiomyopathy and mid-ventricular
obstruction. Eur J Echocardiogr. 1:277–280. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang YJ, Fan CM, Yuan JQ, Wang SY, Song
YH, Qiao SB, You SJ, Wang ZM, Duan FJ and Li YS: Effectiveness of
alcohol septal ablation versus transaortic extended myectomy in
hypertrophic cardiomyopathy with midventricular obstruction. J
Interv Cardiol. 29:619–627. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nguyen A, Schaff HV, Nishimura RA, Dearani
JA and Ommen SR: Early outcomes of repair of left ventricular
apical aneurysms in patients with hypertrophic cardiomyopathy.
Circulation. 136:1979–1981. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Opie LH, Commerford PJ, Gersh BJ and
Pfeffer MA: Controversies in ventricular remodelling. Lancet.
367:356–367. 2006. View Article : Google Scholar : PubMed/NCBI
|
